MAOA and Parkinson disease: MAO-A preferentially metabolizes 5-HT and NE, inhibited by clorgyline (an antidepressant), while MAO-B targets DA, inhibited by deprenyl (an anti-Parkinson agent enhancing L-DOPA effects).